Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III
- 17 April 2003
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 129 (4) , 234-238
- https://doi.org/10.1007/s00432-003-0432-z
Abstract
Purpose We studied bone marrow angiogenesis in different stages of multiple myeloma according to the Durie and Salmon classification and its correlations with other disease characteristics. Methods Sixty-five immunohistochemical CD34-stained, paraffin-embedded bone marrow biopsies of multiple myeloma patients and 12 controls were studied. The mean number of microvessels per area in each sample was determined as the microvessel density (MVD). In addition, plasma cell infiltration of the bone marrow, serum β2-microglobulin, immunoglobulin levels, C-reactive protein, and serum calcium concentration were measured in 22 patients with stage I multiple myeloma and in 43 patients in stage II-III. Results In myeloma patients, the bone marrow MVD was significantly higher than in controls (P2, respectively, P=0.005). Additionally, in stage II-III the bone marrow MVD correlated positively with the bone marrow plasma cell infiltration (r=0.55, Pr=0.53, P<0.001), while in stage I patients no correlation could be found. Conclusions Angiogenesis is significantly increased in stage II-III myeloma in comparison to stage I. In stages II-III, bone marrow angiogenesis is correlated with plasma cell infiltration and serum β2-microglobulin levels.Keywords
This publication has 31 references indexed in Scilit:
- Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.2002
- Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell UsJNCI Journal of the National Cancer Institute, 2002
- The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myelomaThe Hematology Journal, 2002
- Therapeutic application of thalidomide in multiple myelomaSeminars in Oncology, 2001
- Cyclooxygenase-2: a novel target for cancer chemotherapy?Zeitschrift für Krebsforschung und Klinische Onkologie, 2001
- Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myelomaEuropean Journal of Haematology, 2001
- Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased VascularityThe American Journal of Pathology, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast CarcinomaNew England Journal of Medicine, 1991